EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structure-based design of an immunogenic, conformationally stabilized FimH antigen for a urinary tract infection vaccine

Natalie C Silmon de Monerri iD, Ye Che, Joshua A Lees, Jayasankar Jasti, Huixian Wu, Matthew C Griffor, Srinivas Kodali, Julio Cesar Hawkins, Jacqueline Lypowy, Christopher Ponce, Kieran Curley, Alexandre Esadze und 11 weitere

PLOS Pathogens · 2025

DOI: 10.1371/journal.ppat.1012325 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von Natalie C Silmon de Monerri und 22 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Research and Development, Pfizer Inc, Pearl River, New York, New York, United States of America. Hauptthemen laut MEDLINE: Fimbriae Proteins, Adhesins, Escherichia coli, Urinary Tract Infections, Escherichia coli Infections. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adhesion of E. coli to the urinary tract epithelium is a critical step in establishing urinary tract infections. FimH is an adhesin positioned on the fimbrial tip which binds to mannosylated proteins on the urinary tract epithelium via its lectin domain (FimH LD ). FimH is of interest as a target of vaccines to prevent urinary tract infections (UTI). Previously, difficulties in obtaining purified recombinant FimH from E. coli along with the poor inherent immunogenicity of FimH have hindered the development of effective FimH vaccine candidates. To overcome these challenges, we have devised a novel production method using mammalian cells to produce high yields of homogeneous FimH protein with comparable biochemical and immunogenic properties to FimH produced in E. coli. Next, to optimize conformational stability and immunogenicity of FimH, we used a computational approach to design improved FimH mutants and evaluated their biophysical and biochemical properties, and murine immunogenicity using a bacterial adhesion inhibition assay. This approach identified an immunogenic FimH variant (FimH- d onor- s trand complemented with Fim G peptide ‘triple mutant’, FimH-DSG TM) capable of blocking bacterial adhesion that is produced at high yields in mammalian cells. By x-ray crystallography, we confirmed that the stabilized structure of the FimH LD in FimH-DSG TM is similar to native FimH on the fimbrial tip. Characterization of monoclonal antibodies elicited by FimH-DSG that can block bacterial binding to mannosylated surfaces identified 4 non-overlapping binding sites whose epitopes were mapped via a combinatorial cryogenic electron microscopy approach. Novel inhibitory epitopes in the lectin binding FimH were identified, revealing diverse functional mechanisms of FimH-directed antibodies with relevance to FimH-targeted UTI vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fimbriae ProteinsAdhesins, Escherichia coliUrinary Tract InfectionsEscherichia coli InfectionsEscherichia coli VaccinesAnimalsMiceBacterial AdhesionEscherichia coliProtein ConformationHumansFemale

Substanzen

Fimbriae ProteinsfimH protein, E coliAdhesins, Escherichia coliEscherichia coli Vaccines

Autor:innen und Institutionen

  • Vaccine Research and Development, Pfizer Inc, Pearl River, New York, New York, United States of America.
  • Discovery Sciences, Pfizer Inc, Groton, Connecticut, United States of America.

ORCID-Profile: Natalie C Silmon de Monerri

Förderung

  • Pfizer Inc
  • Pfizer

Zitieren

APA

Silmon de Monerri, N. C., Che, Y., Lees, J. A., Jasti, J., Wu, H., Griffor, M. C., Kodali, S., Hawkins, J. C., Lypowy, J., Ponce, C., Curley, K., Esadze, A., Carcamo, J., McLellan, T., Keeney, D., Illenberger, A., Matsuka, Y. V., Shanker, S., Chorro, L., …, & Donald, R. G. K. (2025). Structure-based design of an immunogenic, conformationally stabilized FimH antigen for a urinary tract infection vaccine. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012325

Vancouver

Silmon de Monerri NC, Che Y, Lees JA, Jasti J, Wu H, Griffor MC, et al. Structure-based design of an immunogenic, conformationally stabilized FimH antigen for a urinary tract infection vaccine. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1012325

BibTeX
@article{SilmondeMonerri2025,
  author = {Silmon de Monerri, Natalie C and Che, Ye and Lees, Joshua A and Jasti, Jayasankar and Wu, Huixian and Griffor, Matthew C and Kodali, Srinivas and Hawkins, Julio Cesar and Lypowy, Jacqueline and Ponce, Christopher and Curley, Kieran and Esadze, Alexandre and Carcamo, Juan and McLellan, Thomas and Keeney, David and Illenberger, Arthur and Matsuka, Yury V and Shanker, Suman and Chorro, Laurent and Gribenko, Alexey V and Han, Seungil and Anderson, Annaliesa S and Donald, Robert G K},
  title = {Structure-based design of an immunogenic, conformationally stabilized FimH antigen for a urinary tract infection vaccine},
  journal = {PLOS Pathogens},
  year = {2025},
  doi = {10.1371/journal.ppat.1012325}
}
Kostenlos starten →